The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | Recent advances in the targeting of FLT3 in AML
There are now several novel drugs targeting the protein kinase FLT3 in patients with acute myeloid leukemia (AML). Here, Keith Pratz, MD, of Johns Hopkins University, Baltimore, MD, discusses the clinical implications of these new agents and why they may provide an advantage over current treatments. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
